Financing channel feed

Cana­di­an CD­MO se­cures more fund­ing to get its man­u­fac­tur­ing site up and run­ning

Last year
Manufacturing

Dol­lars flow with three new pub­lic of­fer­ings, two pri­vate place­ments

Last year

Roger Perl­mut­ter builds Eikon's pipeline with deal-mak­ing flur­ry, rais­ing $106M more

Last year
Deals

Ex­clu­sive: With $8M, neu­ro start­up Mod­u­lo Bio emerges to test small mol­e­cules for ALS, de­men­tia in CEO’s per­son­al mis­sion

Last year
Startups
AI

Ex-Turn­ing Point ex­ecs plan to have their next bet, Aven­zo, on the Nas­daq next sum­mer

Last year
Startups

Car­mot rais­es an­oth­er $150M for obe­si­ty drugs, though race by com­peti­tors is well un­der­way

Last year
Startups
R&D

Ab­Cellera and Cana­da to in­vest $500M+ to boost an­ti­body man­u­fac­tur­ing and re­search

Last year
Discovery
Manufacturing

Dutch biotech rais­es €30M for up­scaled man­u­fac­tur­ing, pi­lot study of blood clot­ting drug

Last year

Phath­om Phar­ma­ceu­ti­cals re­sub­mits NDA for acid block­er, bags $130M+ from of­fer­ing

Last year
R&D

Chron­ic wound biotech rais­es $26M in Se­ries D to ex­pand blood clot prod­ucts

Last year

With Mod­er­na wind­fall, Har­vard pro­fes­sor and in­te­grins leg­end Tim Springer do­nates $210M to his In­sti­tute for Pro­tein In­no­va­tion

Last year
People

El­e­vate­Bio snags the year's largest raise with $401M Se­ries D, plus a re­search part­ner­ship with No­vo

Last year
Cell/Gene Tx

Lark­spur Bio­sciences kicks off with $30M+, hunt­ing for new on­col­o­gy im­munother­a­pies

Last year
Startups

Icosavax push­es for­ward com­bo RSV-hM­PV vac­cine and an­nounces di­rect stock of­fer­ing

Last year
R&D

Back Bay makes deal with Nor­way's DNB in bank­ing and ad­vi­so­ry part­ner­ship

Last year
Deals

Amit Mun­shi has more than $300M and a start­up CSO out to pi­o­neer next-gen RNA ther­a­peu­tics. Once again, he’s think­ing big

Last year
Bioregnum

Krys­tal Biotech rais­es $160M via PIPE on heels of FDA ap­proval for gene ther­a­py

Last year

Chas­ing the KRAS field, Quan­ta Ther­a­peu­tics bags $50M for two 2024 clin­i­cal tri­als

Last year
Startups

Co­manche lines up tri­al for preeclamp­sia siR­NA with Mod­er­na, Med­i­cines Com­pa­ny vets and GV back­ing

Last year
Startups
R&D

Short­ly af­ter Clay Sie­gall’s ar­rival, Philip Low’s Mor­phim­mune nabs funds for twist on can­cer ther­a­pies

Last year
Startups

Ca­balet­ta lands $84M from stock sale af­ter FDA clears INDs for CD19 CAR-T in au­toim­mune dis­eases

Last year

Ex­clu­sive: Myeloid Ther­a­peu­tics rais­es $73M, bring­ing in ARCH ahead of in vi­vo pro­gram en­ter­ing the clin­ic

Last year

On a per­son­al mis­sion for his daugh­ter, Paul Bres­ge launch­es an­oth­er eye dis­ease biotech with $100M for Ray Ther­a­peu­tics

Last year
Startups
Cell/Gene Tx

Bound­less Bio snags $100M to en­ter clin­ic and fight can­cer by tar­get­ing cir­cu­lar DNA bits

Last year
First page Previous page 32333435363738 Next page Last page
A service from the Financial Times